BioNTech SE (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $142.72.

Several analysts have recently weighed in on BNTX shares. BMO Capital Markets restated an "outperform" rating on shares of BioNTech in a research report on Monday, December 2nd. The Goldman Sachs Group upgraded shares of BioNTech from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Evercore ISI upgraded shares of BioNTech from an "in-line" rating to an "outperform" rating and boosted their price objective for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. HC Wainwright restated a "buy" rating and set a $150.00 price objective on shares of BioNTech in a research report on Monday, November 18th. Finally, Canaccord Genuity Group boosted their price objective on shares of BioNTech from $171.00 to $171.44 and gave the stock a "buy" rating in a research report on Wednesday, November 27th.

BioNTech Stock Down 0.7 %

BioNTech stock traded down $0.77 during trading on Monday, reaching $114.50. The stock had a trading volume of 441,992 shares, compared to its average volume of 723,303. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The business has a 50 day moving average price of $117.24 and a 200 day moving average price of $108.95. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market cap of $27.45 billion, a PE ratio of -54.52 and a beta of 0.17.

Hedge Funds Weigh In On BioNTech

Several institutional investors have recently bought and sold shares of the company. LPL Financial LLC increased its stake in BioNTech by 4.9% in the 4th quarter. LPL Financial LLC now owns 38,860 shares of the company's stock valued at $4,428,000 after buying an additional 1,800 shares during the period. Lingohr Asset Management GmbH purchased a new stake in shares of BioNTech during the 4th quarter worth $357,000. Midwest Professional Planners LTD. boosted its position in shares of BioNTech by 5.8% during the 4th quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock worth $462,000 after purchasing an additional 222 shares in the last quarter. LBP AM SA boosted its position in shares of BioNTech by 2.1% during the 4th quarter. LBP AM SA now owns 252,918 shares of the company's stock worth $28,820,000 after purchasing an additional 5,085 shares in the last quarter. Finally, Vestcor Inc boosted its position in shares of BioNTech by 50.0% during the 4th quarter. Vestcor Inc now owns 9,900 shares of the company's stock worth $1,128,000 after purchasing an additional 3,300 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.